eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Cancer cells express high levels of programmed death ligand 1 (PD-L1), a ligand of the
programmed cell death protein 1 (PD-1) receptor on T cells, allowing tumors to suppress T …
programmed cell death protein 1 (PD-1) receptor on T cells, allowing tumors to suppress T …
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden… - Nature …, 2020 - utsouthwestern.elsevierpure.com
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
S Suresh, B Chen, J Zhu, RJ Golden, C Lu… - Nature Cancer, 2020 - europepmc.org
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
[引用][C] eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden, C Lu, BM Evers… - Nature Cancer, 2020 - cir.nii.ac.jp
[PDF][PDF] eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden, C Lu, BM Evers… - academia.edu
Correspondence: Kathryn. ODonnell@ UTSouthwestern. edu. Author contributions-
Conception and Design, KAO, SS Investigation, SS, JZ, SJ, CMK, BS, NN; Methodology …
Conception and Design, KAO, SS Investigation, SS, JZ, SJ, CMK, BS, NN; Methodology …
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden, C Lu… - Nature …, 2020 - pubmed.ncbi.nlm.nih.gov
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden… - Nature …, 2020 - mdanderson.elsevierpure.com
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
[HTML][HTML] eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
S Suresh, BB Chen, J Zhu, RJ Golden, C Lu… - Nature …, 2020 - ncbi.nlm.nih.gov
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
S Suresh, B Chen, J Zhu, RJ Golden, C Lu… - Nature Cancer, 2020 - europepmc.org
Cancer cells express high levels of PD-L1, a ligand of the PD-1 receptor on T cells, allowing
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …
tumors to suppress T cell activity. Clinical trials utilizing antibodies that disrupt the PD-1/PD …